Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.4793
-0.0336 (-6.55%)
Mar 31, 2025, 2:27 PM EDT - Market open
Century Therapeutics Stock Forecast
IPSC's stock price has decreased by -87.99% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Century Therapeutics stock have an average target of 4.67, with a low estimate of 2.00 and a high estimate of 7.00. The average target predicts an increase of 874.34% from the current stock price of 0.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Century Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +1,360.46% | Mar 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $12 → $5 | Strong Buy | Maintains | $12 → $5 | +943.19% | Mar 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $2 | Buy | Maintains | $4 → $2 | +317.28% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Jan 22, 2025 |
Financial Forecast
Revenue This Year
3.50M
from 6.59M
Decreased by -46.85%
Revenue Next Year
2.04M
from 3.50M
Decreased by -41.75%
EPS This Year
-0.86
from -1.61
EPS Next Year
-1.53
from -0.86
Revenue Forecast
| Revenue | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | 9.5M | 4.2M | 2.5M | |
| Avg | 3.5M | 2.0M | 2.4M | |
| Low | n/a | n/a | 2.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | 43.4% | 19.9% | 21.5% | |
| Avg | -46.9% | -41.7% | 18.0% | |
| Low | - | - | 13.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.37 | -1.16 | -1.24 |
| Avg | -0.86 | -1.53 | -1.20 |
| Low | -1.89 | -1.85 | -1.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.